False Biomarker Discovery Due to Reactivity of a Commercial ELISA for CUZD1 with Cancer Antigen CA125 episode artwork

EPISODE · Oct 4, 2013 · 12 MIN

False Biomarker Discovery Due to Reactivity of a Commercial ELISA for CUZD1 with Cancer Antigen CA125

from Clinical Chemistry Podcast

The discovery phase of proteomics is critical in the identification of suitable markers for exploration and validation of promising new clinical tests. But can laboratories be certain if what they believe they are measuring is, in fact, what they actually measuring?

Episode metadata supplied by the publisher feed · Published Oct 4, 2013

Embed this episode

NOW PLAYING

False Biomarker Discovery Due to Reactivity of a Commercial ELISA for CUZD1 with Cancer Antigen CA125

0:00 12:06

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Clinical Chemistry Podcast?

This episode is 12 minutes long.

When was this Clinical Chemistry Podcast episode published?

This episode was published on October 4, 2013.

Can I download this Clinical Chemistry Podcast episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!